STOCKS TELEGRAPH

Category: Mid Day Movers

  • Acquisition Deal Drives Nano Dimension (NNDM) Shares Higher

    Acquisition Deal Drives Nano Dimension (NNDM) Shares Higher

    After unveiling an acquisition deal, Nano Dimension Ltd. (NASDAQ: NNDM) experienced a notable increase in its share price on the US stock charts today. As of the latest check during current market session, NNDM stock has risen by 15.97%, reaching $2.51.

    Agreement for Acquisition with Desktop Metal, Inc.

    Nano Dimension (NNDM) announced that it has finalized a binding contract with and Desktop Metal, Inc. The agreement states that Nano Dimension will purchase all of Desktop Metal’s outstanding shares in an all-cash deal for $5.50 per share, with the possibility of downward modifications to $4.07 per share as noted.

    This transaction, at $5.50 per share, represents a premium of 27.3% over Desktop Metal’s closing price and a premium of 20.5% over the 30-day VWAP as of July 2, 2024, for a total estimated value of $183 million. This amount could decrease to $4.07 per share or $135 million in total.

    Strategic Integration and Expanded Capabilities

    This merger marks a significant milestone in Nano Dimension’s progression towards becoming a leader in digital manufacturing, particularly in mass manufacturing for critical industrial applications.

    Through this agreement, Desktop Metal will contribute its pioneering and complementary product portfolios to Nano Dimension, enhancing its capacity to serve customers in high-growth industries with a comprehensive range of digital manufacturing technologies for metal, polymer, electronics, casting, ceramics, and micro-polymer applications

    Creating a Comprehensive Additive Manufacturing Leader

    The transaction leverages the strengths of both companies across various end-user applications, Additive Manufacturing (AM) technologies, and material expertise. Nano Dimension is recognized for its leadership in 3D-printed electronics and high-performance polymer, ceramic, and metal applications, powered by DeepCube’s deep learning-based AI.

    Desktop Metal stands out due to its emphasis on large-scale metal and polymer applications using exclusive materials, tools, and sintering techniques. This union aims to establish a long-term business and a pioneering entity in 3D printing, offering innovative solutions that transition from prototyping to mainstream tooling and end-use part production.

    The merged company will be the first AM provider to meet the full spectrum of customer needs from prototyping to production across various critical and high-performance medical and electronics applications in industrial and high-performance materials.

  • Vivakor (VIVK) Stock Rises After Acquisition Update

    Vivakor (VIVK) Stock Rises After Acquisition Update

    Vivakor, Inc. (NASDAQ: VIVK) shares have experienced a significant uptrend today. As of the most recent check during the final hour of today’s regular trading session, VIVK stock had risen by 25.30% to $3.12.

    Acquisition of Endeavor Entities

    Vivakor (VIVK) has provided an update on the progress of its previously announced acquisition of several entities under the umbrella of Endeavor Crude, LLC. These entities include Meridian Equipment Leasing, LLC and its subsidiary CPE Gathering MidCon, LLC, Equipment Transport, LLC and its subsidiary ET EmployeeCo, LLC, as well as Silver Fuels Processing, LLC (collectively known as the “Endeavor Entities”).

    The Endeavor Entities are experts in the transportation, collection, blending, storage, remediation, and repurposing of generated water, oilfield waste, and crude oil and its byproducts. Their operations encompass truck and pipeline transportation of these commodities.

    Closing Conditions

    As previously communicated, the completion of the acquisition is contingent upon the fulfillment of several conditions. Those include due diligence satisfactory to the parties, delivery of audited financials for the periods ended December 31, 2022 and 2023, delivery of unaudited financial statements for any quarterly periods in 2024.

    Vivakor is also to receive a satisfactory fairness opinion to the underlying transaction, approval under the Hart Scott Rodino Act (HSR), as well as other customary closing conditions. After receiving audited financial statements for the corresponding fiscal years 2022 and 2023, Vivakor is wrapping up its due diligence. The Company plans to submit its pre-merger HSR notification soon. As of right present, Vivakor plans to close the Endeavor Entities purchase in the third quarter of 2024.

    Strategic Implications and Future Prospects

    The Endeavor Entities provide Vivakor a fantastic chance to bring together a number of connected companies under one roof, increasing the company’s profitability and diversification. The remediation processing facilities being built by Vivakor will make it easier to collect, reuse, and dispose of waste products and petroleum byproducts that are produced during the treatment and processing of oilfield waste.

    Through the creation of synergies between business sectors, Vivakor is able to optimize operations and more fully capture the value chain, leading to notable cost reductions and positive free cash flow to support ongoing expansion and ongoing operations.

  • Roadzen (RDZN) Experiences Significant Stock Surge Post-Earnings Report

    Roadzen (RDZN) Experiences Significant Stock Surge Post-Earnings Report

    Following the release of its earnings report, shares of Roadzen, Inc. (NASDAQ: RDZN) have surged significantly on the US stock charts. As of the latest current-market check, RDZN stock has soared by 72.84%, reaching $2.80.

    Impressive Financial Performance and Market Expansion

    Roadzen (RDZN) revealed its financial results for the year ended on March 31, 2024, highlighting a remarkable year with significant revenue growth and a solid path toward profitability. The business has maintained strong growth in India while significantly increasing its footprint in the US and UK markets.

    The advanced technology group and AI research lab of RDZN now support a comprehensive global client base and infrastructure. This includes 101 large enterprise clients, such as leading insurers, automakers, and extensive fleets, along with approximately 3,200 small and medium businesses, including agents, brokers, dealerships, and smaller fleets.

    Revenue for the year reached $46.7 million, a 245% increase over the previous year, driven by incremental revenue from acquisitions in the U.S. and U.K. as well as ongoing growth in India.

    As of March 31, 2024, Roadzen had secured 33 insurance customer agreements, up from 26 in the previous year, and 68 automotive customer agreements, compared to 23 in the prior year. Additionally, the number of agents and fleet customer agreements rose to approximately 3,200, compared to about 2,000 in the prior year.

    Growth in Brokerage Segment and Strategic Streamlining

    In the brokerage segment, Roadzen sold 324,293 policies during fiscal 2024, generating $61.8 million in Gross Written Premium (GWP), compared to 258,546 policies sold in the previous year for $38.0 million in GWP. This represents a 25.5% increase in policies sold and a 62.6% increase in GWP.

    Looking forward, Roadzen anticipates sustaining its momentum and establishing itself as a leader in vertical AI for auto insurance within the public markets. The company plans to leverage the robust foundation it has built over the past year.

    In preparation for the 2024 year-end, Roadzen has focused on simplifying and streamlining its organizational structure and internal financial reporting protocols, readying the company for scaling and another breakout year in 2025.

  • Ocean Power (OPTT) Stock: Strategic Partnership Boosts Market Performance

    Ocean Power (OPTT) Stock: Strategic Partnership Boosts Market Performance

    Announcing a strategic partnership, Ocean Power Technologies, Inc. (NYSE: OPTT) shares are experiencing significant growth in the current market session. As of the latest update, OPTT stock has surged by 74.40% on the US stock charts, reaching $0.4817.

    Ocean Power Partners with Unique Group

    Ocean Power (OPTT) has formed a collaboration with Unique Group, a UAE-based global leader in subsea technologies and engineering, which offers a diverse range of products and services to various industry sectors.

    Unique Group, employing over 600 staff across 20 operational bases worldwide, will work with Ocean Power to deploy OPTT’s existing WAM-V Unmanned Surface Vehicles (USVs) in the UAE and other countries within the Gulf Cooperation Council region.

    This integration of Ocean Power’s commercially available vehicles with Unique Group’s prominent position in the UAE’s offshore energy sector is expected to accelerate the adoption of USVs in the region. Unique Group’s extensive knowledge of the local industry and established footprint will enable more efficient maintenance and services.

    Global Expansion and Technological Advancements

    Collaborating with Unique Group will further expedite Ocean Power’s efforts to deploy USVs on a global scale. Ocean Power is optimistic about the prospects of expanding into the UAE and commends the local industry’s progressive approach to adopting autonomous technologies.

    In addition to this partnership, Ocean Power has recently signed an Original Equipment Manufacturer (OEM) agreement with Teledyne Marine, a division of Teledyne Technologies Inc. (NYSE: TDY), a key supplier in maritime technology, including connectors, instruments, and vehicles.

    This strategic alliance aims to enhance OPTT’s product offerings and drive innovation within the industry, providing customers with a comprehensive turnkey system. By joining forces with Teledyne Marine, Ocean Power will leverage Teledyne’s best-in-class offerings to deliver superior sensor and ocean technology products to its customers.

    Alignment of Objectives and Future Prospects

    The partnership between Ocean Power and Teledyne aligns perfectly with the core objectives of both companies, enabling key platform providers to expand their operational capabilities through critical technology enablers and top-tier products. Furthermore, Ocean Power aims to broaden this partnership to achieve new product offerings, fostering innovation and growth in the maritime technology sector.

  • Oramed Pharmaceuticals (ORMP): Shareholder Letter Spurs Bullish Trend

    Oramed Pharmaceuticals (ORMP): Shareholder Letter Spurs Bullish Trend

    After releasing a letter to shareholders, Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) shares has seen a significant increase on the US stock charts. As of the latest current-market check, ORMP stock price increased 18.82% to $2.66.

    Program For Stock Repurchases And Strategic Update

    Nadav Kidron, the CEO of Oramed Pharmaceuticals (ORMP), sent a detailed letter to the company’s stockholders. This letter is in response to Oramed’s recent announcement of its $20 million stock repurchase program, which was made in order to demonstrate the company’s belief in its inherent worth and future prospects. The letter gave stockholders a thorough rundown of the business’s latest operations and strategic advancements.

    Financial Milestones And Regulatory Engagements

    In the shareholder letter, Oramed detailed the repayment schedule from Scilex Holding Company for its Senior Secured Note, which commenced on December 21, 2023. Thus far, Oramed has received $40 million out of the total $102 million principal, with the next $20 million installment due in September.

    A major amount of the projected returns from this strategic investment is represented by this payback, and Oramed has been aggressively pursuing conversations with the U.S. Food and Drug Administration (FDA) about a new Phase 3 procedure.

    This refined protocol is strategically designed to target specific patient subgroups identified as significant responders through thorough analysis of both Phase 2 and Phase 3 data.

    Joint Venture And Future Prospects

    Oramed also announced the formation of a joint venture with its long-term partner, Hefei Tianhui Biotech Co., Ltd. (HTIT), centered around Oramed’s innovative oral drug delivery technology. The U.S.-based joint venture aims to develop, market, and commercialize products from Oramed’s oral insulin and Protein Oral Delivery (POD) pipeline, leveraging HTIT’s advanced manufacturing capabilities.

    The joint venture will be bolstered by a substantial capital infusion, with HTIT committing $70 million in cash and Oramed contributing $25 million in cash and stock. These funds are earmarked to support the successful completion of the Phase 3 trial in the U.S., alongside other critical clinical and business initiatives.

    Oramed and HTIT are also investigating ways to use HTIT’s production capacity and the upcoming introduction of oral insulin sales. Recent advancements and strategic initiatives by Oramed Pharmaceuticals demonstrate the company’s dedication to improving its cutting-edge therapies and increasing shareholder value.

  • Strategic Announcements Propel DiaMedica (DMAC) Stock Surge

    Strategic Announcements Propel DiaMedica (DMAC) Stock Surge

    Following a couple of strategic developments, DiaMedica Therapeutics Inc.’s (NASDAQ: DMAC) shares are surging on US stock charts today. As of the most recent check, DMAC stock has gained 30.97% during the current-market session, reaching $2.96.

    Agreement Details

    DiaMedica (DMAC) has signed definitive agreements to offer its common shares to accredited investors in a private placement. DMAC expects to receive $11.8 million in gross proceeds from this transaction. As per the conditions mentioned in the securities purchase agreements, DiaMedica will issue 4,720,000 common shares at a $2.50 per share purchase price.

    The anticipated closing date of this private placement is June 28, 2024, subject to the satisfaction of normal closing requirements. The net proceeds of this private placement will be used to further DiaMedica’s efforts related to product development and clinical research, particularly with regard to DM199.

    This involves increasing clinical research on preeclampsia and sponsoring the crucial Phase 2/3 ReMEDy2 study for the treatment of acute ischemic stroke. The money will also go toward general business objectives and additional working capital, extending DiaMedica’s financial runway until the third quarter of 2026.

    Expanding Clinical Trial To Preeclampsia

    Additionally, DiaMedica has disclosed that it intends to broaden clinical studies into preeclampsia, a hypertensive pregnancy disease for which there are no FDA-approved therapies and huge unmet medical needs. Preeclampsia is a potentially fatal illness that is marked by newly developed hypertension, proteinuria, and/or end organ malfunction. It poses serious dangers to both the mother and the unborn child.

    As of right now, neither Europe nor the United States have authorized therapies for preeclampsia. Studies show that DM199 can successfully reduce blood pressure. DM199 is a big molecule protein that has been demonstrated in animal experiments to not penetrate the placental barrier, potentially providing a considerable safety advantage in illnesses associated to pregnancy, unlike small molecule anti-hypertensives, which are contraindicated.

    With up to 120 participants and an expected cost of around $1.5 million, the preeclampsia study is planned to be very cost-efficient and provide a solid proof of concept for this indication.

  • Major Contract Win Propels American Superconductor (AMSC) Shares Upward

    Major Contract Win Propels American Superconductor (AMSC) Shares Upward

    Following the announcement of a significant contract acquisition, shares of American Superconductor Corporation (NASDAQ: AMSC) have experienced a notable surge on the US stock charts today. As of the latest current-market session update, AMSC’s stock price had risen by 9.68%, reaching $25.83.

    Landmark Multi-Year Contract

    American Superconductor (AMSC) has secured a multi-year and multi-unit delivery contract valued at approximately $75 million. The contract, awarded by Irving Shipbuilding Inc. of Halifax, Canada, encompasses the provision of Ship Protection Systems hardware and associated engineering services for the Royal Canadian Navy.

    Irving Shipbuilding, responsible for constructing over 80% of Canada’s Navy fleet, will receive the first Ship Protection System in 2026. This system, already integrated into the U.S. Navy’s San Antonio Class amphibious ship platform, will be adapted for use in the Canadian Surface Combatant Ships (CSC).

    The compact design of AMSC’s technology facilitates the incorporation of the Ship Protection System into the densely outfitted CSC ship design, enhancing mine protection capabilities.

    Strategic Diversification And Future Collaborations

    This contract signifies AMSC’s initial delivery of Ship Protection production systems to an allied navy, marking a milestone in the company’s strategic efforts to diversify its business and expand its global presence.

    AMSC will collaborate with Irving Shipbuilding Inc. and the Royal Canadian Navy to implement the Ship Protection Systems in the CSC ships and anticipates extending its partnership with other allied navies.

    The fundamental elements of the Ship Protection System may be modified for use in different maritime contexts, which is consistent with AMSC’s objective of expanding the use of high-temperature superconductor (HTS) technology in naval fleets.

    Developing Superconductor Technology’s Scope

    A sophisticated degaussing system is one of American Superconductor’s HTS-based products, sometimes known as “Ship Protection Systems,” which are intended to lessen a ship’s magnetic signature and lower the possibility that underwater mines may be detected and cause damage.

    This cutting-edge degaussing technology is a prime example of AMSC’s dedication to improving naval defense with new solutions. By reducing the magnetic footprint of naval vessels, AMSC’s systems significantly bolster a ship’s defenses against modern maritime threats.

  • Management Transition Boosts Barnes & Noble Education (BNED) Stock

    Management Transition Boosts Barnes & Noble Education (BNED) Stock

    Following a large slump and subsequent stock split, Barnes & Noble Education, Inc. (NYSE: BNED) shares are showing prospects of recovery on the US stock market. Over the course of the current-market session, BNED shares rose 9.16% to $7.63. A significant change in the company’s leadership is also credited with this improvement in investor opinion.

    Leadership Changes

    With effect from June 11, 2024, Jonathan Shar has been named as the next CEO by the Barnes & Noble Education’s (BNED) Board of Directors. Michael P. Huseby, who left his role as CEO on the same day, is succeeded by Mr. Shar. The company’s future path seems to have garnered investor trust thanks to this management change.

    Strategic Investments And Financial Resilience

    With a strong focus on customer service and creative solutions for schools and institutions, Barnes & Noble Education has continuously outperformed its competitors in this area. Recent equity investments and refinancing transactions have fortified the company’s financial stability, positioning it more favorably to serve its academic partners and customers.

    The company successfully concluded significant equity and refinancing transactions involving Immersion Corporation and certain existing stockholders and strategic partners. These transactions have considerably strengthened BNED’s balance sheet with an infusion of over $100 million in new equity, setting a robust foundation for future growth and profitability.

    Enhanced Financial Flexibility

    Barnes & Noble Education secured gross proceeds of $95 million in new equity capital through a $50 million equity investment and a $45 million fully backstopped equity rights offering. After transaction costs, this capital influx resulted in approximately $80 million in net cash proceeds.

    Additionally, $34 million in outstanding principle and accrued interest were exchanged into shares of common stock by current second lien lenders, which included Fanatics, Lids, and VitalSource Technologies affiliates.

    Furthermore, Barnes & Noble Education added access to a $325 million revolving credit facility that matures in 2028 by amending and extending its current asset-based lending arrangement with Bank of America, N.A. This amended facility significantly enhances BNED’s financial flexibility and reduces annual interest expenses, further solidifying the company’s financial position.

  • What Is Driving Sintx Technologies (SINT) Stock Higher Today?

    What Is Driving Sintx Technologies (SINT) Stock Higher Today?

    Sintx Technologies, Inc. (NASDAQ: SINT) has witnessed a notable rise in its stock value on the US charts following its achievement of compliance with the NASDAQ listing requirements. As of the last check during current-market session, SINT stock was up 9.57% to $5.04.

    Stock Market Resurgence

    After receiving confirmation from The Nasdaq on June 11, 2024, Sintx Technologies made a public announcement stating that it has complied with the $1.00 minimum bid price threshold required to remain listed on The Nasdaq Capital Market. As a result, the previously pending listing issue has been resolved.

    Nevertheless, Sintx Technologies will remain under a “Mandatory Panel Monitor” for one year from the date of compliance. Should the company fail to maintain a minimum $1.00 closing bid price for 30 consecutive business days within this period, Nasdaq will initiate delisting procedures without granting an additional grace period to regain compliance. In such a scenario, Sintx Technologies retains the right to request a new hearing to address the deficiency.

    Strategic Contract Acquisition

    In a significant development, Sintx Technologies’ wholly-owned subsidiary, Technology Assessment and Transfer, Inc. (TA&T), has secured a three-month, $75,000 Phase I Small Business Innovation Research (SBIR) contract from AFWERX. This contract, focusing on the Enhanced Sinterability of Complex-Shaped 3D Printed Silicon Nitride (Si3N4), aims to overcome material challenges in propulsion and guidance technologies for next-generation high-temperature Department of the Air Force systems.

    Through this partnership, TA&T aims to enhance its innovative capabilities to bolster United States defense. Success in this initial phase may pave the way for TA&T/Sintx Technologies to secure a Phase II AFWERX contract valued at up to $1.25 million over 21 months.

    Pioneering 3D Printing In Silicon Nitride

    Sintx Technologies is addressing a critical gap in the industry: while there is considerable activity in 3D printing complex shapes of silicon nitride, there remains a lack of demonstrated production of silicon nitride parts that meet specific performance and repeatability standards. Leveraging its extensive experience with the silicon nitride material family and TA&T’s expertise in ceramic 3D printing, Sintx Technologies is uniquely positioned to lead advancements in this field.

  • Bullish Trend In NanoViricides (NNVC) Shares Following Promising Clinical Findings

    Bullish Trend In NanoViricides (NNVC) Shares Following Promising Clinical Findings

    Following the release of encouraging clinical trial data, shares of NanoViricides, Inc. (NYSE: NNVC) are demonstrating a bullish trend on US stock charts. As of the latest current-market check, NNVC stock increased by 7.92% to $3.27.

    Breakthrough Findings On NV-387

    NanoViricides (NNVC) reported that its leading clinical-stage broad-spectrum antiviral drug candidate, NV-387, exhibits an ideal flat blood concentration profile for an extended duration upon oral administration in two different animal models. This rare but highly desirable extended flat time profile of NV-387 in the bloodstream enables a sustained antiviral effect over a prolonged period, allowing for infrequent dosing regimens.

    Specifically, the blood concentration of NV-387 peaked within the first hour and remained nearly constant for eight hours or longer. Subsequently, the concentration declined to baseline at around twelve hours following the oral administration of the initial dose. This was consistently observed in studies involving rats and dogs.

    Efficacy Across Multiple Models

    Additionally, NanoViricides recently reported that when NV-387 was administered as a slow bolus intravenous infusion, it resulted in a relatively flat blood concentration plateau with a very slow decline over a 24-hour period in a cynomolgus monkey model. The company had previously demonstrated that orally administered NV-387 produced strong antiviral effects against several respiratory viruses.

    In lethal infections with hCoV-NL63, RSV, and Influenza A/H3N2, orally administered NV-387 outperformed approved therapeutics where available. Notably, in a rat model of deadly lung infection with RSV A2, NV-387 allowed for the full recovery from RSV infection.

    Potential Revolutionary Antiviral Agent

    First-in-class, broad-spectrum antiviral medication NV-387, may revolutionize treatment for viruses including RSV, COVID-19, influenza, and maybe others. NNVC’s claim is also supported by non-clinical pharmacokinetic studies of the medication when administered orally that NV-387’s systemic circulation and direct antiviral actions are responsible for the strong antiviral effects shown in animal efficacy trials.

    NanoViricides also highlighted that NV-387 may be among the first or one of the few nanomedicines effective upon oral administration, a notable advancement given that nanomedicines are typically restricted to injectable or topical delivery methods.